Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
IBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.83 - $7.48
Previous CloseN/A
Volume1.20M
Average Volume (3M)7.09M
Market Cap
$2.16B
Enterprise Value$3.33B
Total Cash (Recent Filing)$61.59M
Total Debt (Recent Filing)$526.27M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Aug 06, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding912,250,060
10 Day Avg. Volume8,965,093
30 Day Avg. Volume7,085,739
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue106.65
Enterprise Value/Gross Profit123.21
Enterprise Value/Ebitda-15.55
Forecast
1Y Price Target
$6.33Price Target Upside167.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Global StrategyThe U.K. approval marks a key international milestone for Anktiva, representing a significant step in ImmunityBio's global strategy and affirming the strength of Anktiva’s underlying data.
Market PenetrationThe U.K. authorization not only creates an incremental revenue opportunity but also establishes a foothold for broader EU market penetration, positioning Anktiva as a differentiated immunotherapy platform beyond the U.S. system.
Sales GrowthThe market-driven pricing environment and rapid payer engagement in the U.S. have fueled strong early adoption and sales growth for Anktiva.
Bears Say
Development ChallengesFor small or cash-limited biotech companies, addressing an RTF can be especially challenging if major development work is needed.
Regulatory ChallengesImmunityBio announced it received a surprising Refusal to File (RTF) letter from the FDA regarding its supplemental BLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC patients with papillary-only disease.
Regulatory UncertaintyThe RTF letter introduces regulatory uncertainty, despite the identical treatment protocol between CIS and papillary cohorts.
ImmunityBio News
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $1.83 and its highest was $7.48 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $2.16B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Aug 06, 2025 which is in 2 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on May 12, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.022.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.11.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 912,250,060 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went up 14.01%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in IBRX
ImmunityBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.33 (167.09% Upside)
$6.33 (167.09% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.52%
12-Months-Change
Fundamentals
Return on Equity
78.99%
Trailing 12-Months
Asset Growth
-24.19%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc. (IBRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies that harness the power of the immune system to treat cancer and infectious diseases. Operating primarily in the biotechnology and pharmaceuticals sectors, the company focuses on developing and commercializing a diverse portfolio of immunotherapy products, including cell therapies, antibody therapies, and vaccines, aimed at providing long-term, durable responses in patients.
IBRX Stock 12 Month Forecast
Average Price Target
$6.33
▲(167.09%Upside)
Technical Analysis
Catalyst Pharma
―
Immunovant
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Immunocore Holdings
―
Ownership Overview
74.12% Insiders
2.86% Mutual Funds
0.04% Other Institutional Investors
18.80% Public Companies and
Individual Investors